Loading…

Astaxanthin Ameliorates Diabetic Retinopathy in Swiss Albino Mice via Inhibitory Processes of Neuron-Specific Enolase Activity

Retinopathy is one of the most common complications of diabetes mellitus. Diabetic retinopathy (DR) occurs due to microvascular damage in retinal tissues provoked by high blood sugar levels. The available drugs for DR are limited. Astaxanthin (AST) has anti-hypertensive, anti-obesity, and anti-diabe...

Full description

Saved in:
Bibliographic Details
Published in:Processes 2022-07, Vol.10 (7), p.1318
Main Authors: Subramanian, Aswinprakash, Thirunavukkarasu, Jayaraman, Muthuraman, Arunachalam
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c295t-28a473ca2458541f3b4512f09949b90a0db1223efe0948d419d9264cc8f872d23
cites cdi_FETCH-LOGICAL-c295t-28a473ca2458541f3b4512f09949b90a0db1223efe0948d419d9264cc8f872d23
container_end_page
container_issue 7
container_start_page 1318
container_title Processes
container_volume 10
creator Subramanian, Aswinprakash
Thirunavukkarasu, Jayaraman
Muthuraman, Arunachalam
description Retinopathy is one of the most common complications of diabetes mellitus. Diabetic retinopathy (DR) occurs due to microvascular damage in retinal tissues provoked by high blood sugar levels. The available drugs for DR are limited. Astaxanthin (AST) has anti-hypertensive, anti-obesity, and anti-diabetic properties. However, the therapeutic effect of AST on DR remains elusive. The present study is designed to investigate the effects of AST on DR via inhibition of neuron-specific enolase (NSE) activity. DR was induced by the administration of streptozotocin (STZ, 35 mg/kg: intraperitoneal; and 20 μL of STZ: intravitreal) in mice. AST (10 and 20 mg/kg) was administered orally (p.o.) for 21 days. The DR associated visual changes were assessed at different time intervals via optokinetic motor response (OMR) and penta-maze (PM) tests. Blood glucose level as well as retinal catalase, lactate dehydrogenase (LDH), & neuron-specific enolase (NSE) were estimated. The reference drug i.e., dexamethasone (DEX, 10 mg/kg; p.o.) was administered for 21 days. The administration of AST showed significant ameliorative potential in DR. Hence, AST can be used as a natural medicine for the management of DR due to its potential antioxidant, anti-diabetic, and NSE inhibitory properties.
doi_str_mv 10.3390/pr10071318
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2694025061</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2694025061</sourcerecordid><originalsourceid>FETCH-LOGICAL-c295t-28a473ca2458541f3b4512f09949b90a0db1223efe0948d419d9264cc8f872d23</originalsourceid><addsrcrecordid>eNpNkE1LAzEQhoMoWGov_oKAN2E1X_uR41KrFuoHVs9LNpuwKdvNmqTVvfjbjVTQOcwMw8Mz8AJwjtEVpRxdDw4jlGOKiyMwIYTkCc9xfvxvPwUz7zcoFse0SLMJ-Cp9EJ-iD63pYblVnbFOBOXhjRG1CkbCl9h7O4jQjjAy6w_jPSy7Oh7hg5EK7o2Ay741tQnWjfDZWam8jwqr4aPaOdsn60FJo6Ns0dtOeAVLGczehPEMnGjReTX7nVPwdrt4nd8nq6e75bxcJZLwNCSkECynUhCWFinDmtYsxUQjzhmvORKoqTEhVGmFOCsahnnDScakLHSRk4bQKbg4eAdn33fKh2pjd66PLyuScYZIijIcqcsDJZ313ildDc5shRsrjKqfiKu_iOk3FkRusw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2694025061</pqid></control><display><type>article</type><title>Astaxanthin Ameliorates Diabetic Retinopathy in Swiss Albino Mice via Inhibitory Processes of Neuron-Specific Enolase Activity</title><source>Publicly Available Content Database</source><source>Coronavirus Research Database</source><creator>Subramanian, Aswinprakash ; Thirunavukkarasu, Jayaraman ; Muthuraman, Arunachalam</creator><creatorcontrib>Subramanian, Aswinprakash ; Thirunavukkarasu, Jayaraman ; Muthuraman, Arunachalam</creatorcontrib><description>Retinopathy is one of the most common complications of diabetes mellitus. Diabetic retinopathy (DR) occurs due to microvascular damage in retinal tissues provoked by high blood sugar levels. The available drugs for DR are limited. Astaxanthin (AST) has anti-hypertensive, anti-obesity, and anti-diabetic properties. However, the therapeutic effect of AST on DR remains elusive. The present study is designed to investigate the effects of AST on DR via inhibition of neuron-specific enolase (NSE) activity. DR was induced by the administration of streptozotocin (STZ, 35 mg/kg: intraperitoneal; and 20 μL of STZ: intravitreal) in mice. AST (10 and 20 mg/kg) was administered orally (p.o.) for 21 days. The DR associated visual changes were assessed at different time intervals via optokinetic motor response (OMR) and penta-maze (PM) tests. Blood glucose level as well as retinal catalase, lactate dehydrogenase (LDH), &amp; neuron-specific enolase (NSE) were estimated. The reference drug i.e., dexamethasone (DEX, 10 mg/kg; p.o.) was administered for 21 days. The administration of AST showed significant ameliorative potential in DR. Hence, AST can be used as a natural medicine for the management of DR due to its potential antioxidant, anti-diabetic, and NSE inhibitory properties.</description><identifier>ISSN: 2227-9717</identifier><identifier>EISSN: 2227-9717</identifier><identifier>DOI: 10.3390/pr10071318</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Albinism ; Angiogenesis ; Animals ; Antihypertensives ; Antioxidants ; Astaxanthin ; Blood ; Catalase ; Dexamethasone ; Diabetes ; Diabetes mellitus ; Diabetic retinopathy ; Edema ; Enzymes ; Glucose ; Hyperglycemia ; L-Lactate dehydrogenase ; Lactate dehydrogenase ; Lactic acid ; Metabolism ; Microvasculature ; Opto-kinetics ; Oral administration ; Phosphopyruvate hydratase ; Proteins ; Retina ; Retinopathy ; Streptozocin</subject><ispartof>Processes, 2022-07, Vol.10 (7), p.1318</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c295t-28a473ca2458541f3b4512f09949b90a0db1223efe0948d419d9264cc8f872d23</citedby><cites>FETCH-LOGICAL-c295t-28a473ca2458541f3b4512f09949b90a0db1223efe0948d419d9264cc8f872d23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2694025061/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2694025061?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,38516,43895,44590,74412,75126</link.rule.ids></links><search><creatorcontrib>Subramanian, Aswinprakash</creatorcontrib><creatorcontrib>Thirunavukkarasu, Jayaraman</creatorcontrib><creatorcontrib>Muthuraman, Arunachalam</creatorcontrib><title>Astaxanthin Ameliorates Diabetic Retinopathy in Swiss Albino Mice via Inhibitory Processes of Neuron-Specific Enolase Activity</title><title>Processes</title><description>Retinopathy is one of the most common complications of diabetes mellitus. Diabetic retinopathy (DR) occurs due to microvascular damage in retinal tissues provoked by high blood sugar levels. The available drugs for DR are limited. Astaxanthin (AST) has anti-hypertensive, anti-obesity, and anti-diabetic properties. However, the therapeutic effect of AST on DR remains elusive. The present study is designed to investigate the effects of AST on DR via inhibition of neuron-specific enolase (NSE) activity. DR was induced by the administration of streptozotocin (STZ, 35 mg/kg: intraperitoneal; and 20 μL of STZ: intravitreal) in mice. AST (10 and 20 mg/kg) was administered orally (p.o.) for 21 days. The DR associated visual changes were assessed at different time intervals via optokinetic motor response (OMR) and penta-maze (PM) tests. Blood glucose level as well as retinal catalase, lactate dehydrogenase (LDH), &amp; neuron-specific enolase (NSE) were estimated. The reference drug i.e., dexamethasone (DEX, 10 mg/kg; p.o.) was administered for 21 days. The administration of AST showed significant ameliorative potential in DR. Hence, AST can be used as a natural medicine for the management of DR due to its potential antioxidant, anti-diabetic, and NSE inhibitory properties.</description><subject>Albinism</subject><subject>Angiogenesis</subject><subject>Animals</subject><subject>Antihypertensives</subject><subject>Antioxidants</subject><subject>Astaxanthin</subject><subject>Blood</subject><subject>Catalase</subject><subject>Dexamethasone</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetic retinopathy</subject><subject>Edema</subject><subject>Enzymes</subject><subject>Glucose</subject><subject>Hyperglycemia</subject><subject>L-Lactate dehydrogenase</subject><subject>Lactate dehydrogenase</subject><subject>Lactic acid</subject><subject>Metabolism</subject><subject>Microvasculature</subject><subject>Opto-kinetics</subject><subject>Oral administration</subject><subject>Phosphopyruvate hydratase</subject><subject>Proteins</subject><subject>Retina</subject><subject>Retinopathy</subject><subject>Streptozocin</subject><issn>2227-9717</issn><issn>2227-9717</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><recordid>eNpNkE1LAzEQhoMoWGov_oKAN2E1X_uR41KrFuoHVs9LNpuwKdvNmqTVvfjbjVTQOcwMw8Mz8AJwjtEVpRxdDw4jlGOKiyMwIYTkCc9xfvxvPwUz7zcoFse0SLMJ-Cp9EJ-iD63pYblVnbFOBOXhjRG1CkbCl9h7O4jQjjAy6w_jPSy7Oh7hg5EK7o2Ay741tQnWjfDZWam8jwqr4aPaOdsn60FJo6Ns0dtOeAVLGczehPEMnGjReTX7nVPwdrt4nd8nq6e75bxcJZLwNCSkECynUhCWFinDmtYsxUQjzhmvORKoqTEhVGmFOCsahnnDScakLHSRk4bQKbg4eAdn33fKh2pjd66PLyuScYZIijIcqcsDJZ313ildDc5shRsrjKqfiKu_iOk3FkRusw</recordid><startdate>20220701</startdate><enddate>20220701</enddate><creator>Subramanian, Aswinprakash</creator><creator>Thirunavukkarasu, Jayaraman</creator><creator>Muthuraman, Arunachalam</creator><general>MDPI AG</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7SR</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>COVID</scope><scope>D1I</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>JG9</scope><scope>KB.</scope><scope>LK8</scope><scope>M7P</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20220701</creationdate><title>Astaxanthin Ameliorates Diabetic Retinopathy in Swiss Albino Mice via Inhibitory Processes of Neuron-Specific Enolase Activity</title><author>Subramanian, Aswinprakash ; Thirunavukkarasu, Jayaraman ; Muthuraman, Arunachalam</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c295t-28a473ca2458541f3b4512f09949b90a0db1223efe0948d419d9264cc8f872d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Albinism</topic><topic>Angiogenesis</topic><topic>Animals</topic><topic>Antihypertensives</topic><topic>Antioxidants</topic><topic>Astaxanthin</topic><topic>Blood</topic><topic>Catalase</topic><topic>Dexamethasone</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetic retinopathy</topic><topic>Edema</topic><topic>Enzymes</topic><topic>Glucose</topic><topic>Hyperglycemia</topic><topic>L-Lactate dehydrogenase</topic><topic>Lactate dehydrogenase</topic><topic>Lactic acid</topic><topic>Metabolism</topic><topic>Microvasculature</topic><topic>Opto-kinetics</topic><topic>Oral administration</topic><topic>Phosphopyruvate hydratase</topic><topic>Proteins</topic><topic>Retina</topic><topic>Retinopathy</topic><topic>Streptozocin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Subramanian, Aswinprakash</creatorcontrib><creatorcontrib>Thirunavukkarasu, Jayaraman</creatorcontrib><creatorcontrib>Muthuraman, Arunachalam</creatorcontrib><collection>CrossRef</collection><collection>Engineered Materials Abstracts</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Materials Research Database</collection><collection>https://resources.nclive.org/materials</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest Biological Science Journals</collection><collection>Materials science collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Processes</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Subramanian, Aswinprakash</au><au>Thirunavukkarasu, Jayaraman</au><au>Muthuraman, Arunachalam</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Astaxanthin Ameliorates Diabetic Retinopathy in Swiss Albino Mice via Inhibitory Processes of Neuron-Specific Enolase Activity</atitle><jtitle>Processes</jtitle><date>2022-07-01</date><risdate>2022</risdate><volume>10</volume><issue>7</issue><spage>1318</spage><pages>1318-</pages><issn>2227-9717</issn><eissn>2227-9717</eissn><abstract>Retinopathy is one of the most common complications of diabetes mellitus. Diabetic retinopathy (DR) occurs due to microvascular damage in retinal tissues provoked by high blood sugar levels. The available drugs for DR are limited. Astaxanthin (AST) has anti-hypertensive, anti-obesity, and anti-diabetic properties. However, the therapeutic effect of AST on DR remains elusive. The present study is designed to investigate the effects of AST on DR via inhibition of neuron-specific enolase (NSE) activity. DR was induced by the administration of streptozotocin (STZ, 35 mg/kg: intraperitoneal; and 20 μL of STZ: intravitreal) in mice. AST (10 and 20 mg/kg) was administered orally (p.o.) for 21 days. The DR associated visual changes were assessed at different time intervals via optokinetic motor response (OMR) and penta-maze (PM) tests. Blood glucose level as well as retinal catalase, lactate dehydrogenase (LDH), &amp; neuron-specific enolase (NSE) were estimated. The reference drug i.e., dexamethasone (DEX, 10 mg/kg; p.o.) was administered for 21 days. The administration of AST showed significant ameliorative potential in DR. Hence, AST can be used as a natural medicine for the management of DR due to its potential antioxidant, anti-diabetic, and NSE inhibitory properties.</abstract><cop>Basel</cop><pub>MDPI AG</pub><doi>10.3390/pr10071318</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2227-9717
ispartof Processes, 2022-07, Vol.10 (7), p.1318
issn 2227-9717
2227-9717
language eng
recordid cdi_proquest_journals_2694025061
source Publicly Available Content Database; Coronavirus Research Database
subjects Albinism
Angiogenesis
Animals
Antihypertensives
Antioxidants
Astaxanthin
Blood
Catalase
Dexamethasone
Diabetes
Diabetes mellitus
Diabetic retinopathy
Edema
Enzymes
Glucose
Hyperglycemia
L-Lactate dehydrogenase
Lactate dehydrogenase
Lactic acid
Metabolism
Microvasculature
Opto-kinetics
Oral administration
Phosphopyruvate hydratase
Proteins
Retina
Retinopathy
Streptozocin
title Astaxanthin Ameliorates Diabetic Retinopathy in Swiss Albino Mice via Inhibitory Processes of Neuron-Specific Enolase Activity
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-31T23%3A41%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Astaxanthin%20Ameliorates%20Diabetic%20Retinopathy%20in%20Swiss%20Albino%20Mice%20via%20Inhibitory%20Processes%20of%20Neuron-Specific%20Enolase%20Activity&rft.jtitle=Processes&rft.au=Subramanian,%20Aswinprakash&rft.date=2022-07-01&rft.volume=10&rft.issue=7&rft.spage=1318&rft.pages=1318-&rft.issn=2227-9717&rft.eissn=2227-9717&rft_id=info:doi/10.3390/pr10071318&rft_dat=%3Cproquest_cross%3E2694025061%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c295t-28a473ca2458541f3b4512f09949b90a0db1223efe0948d419d9264cc8f872d23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2694025061&rft_id=info:pmid/&rfr_iscdi=true